RXEI.US RxElite Inc
- Market cap
- -
- P/E
- -
- P/B
- 0.01x
- ROE
- -231.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2008.
Is RXEI.US undervalued?
Graham numberThe Graham number of RxElite Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
RxElite Inc fundamental analysis
No fundamental analysis for RxElite Inc yet.
RxElite Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About RxElite Inc
RxElite, Inc. engages in the development, manufacture, and marketing of generic prescription drug products in specialty generic markets. Its products include Sterile Liquid Dose products that consist of generic ophthalmic products in unit and multi-dose presentations, sterile unit dose inhalation respiratory products, and injectable drugs. The company, through its subsidiaries, also manufactures active pharmaceutical ingredients for pharmaceutical companies in the United Sta…
Full company profileRxElite Inc financial statements
2008 annualized: Fiscal year 2008 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2008, the balance sheet is the latest quarter. Figures change when the annual report is published.
RxElite Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2005 | 2006 | 2007 | 2008 Anlz |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 25.6M | 14.2M | 2.81M | 12.4M |
| Gross Profit | 1.37M | 301K | 144K | 1.56M |
| Operating Income | -1.02M | -4.26M | -12.3M | -11.6M |
| Net Income | -438K | 7.53M | -17.2M | -32.5M |
| Balance Sheet | ||||
| Total Assets | 10.7M | 8.78M | 21.3M | 33.0M |
| Total Liabilities | 23.0M | 7.52M | 8.96M | 19.0M |
| Shareholders' Equity | -12.3M | 1.26M | 12.3M | 14.1M |
| Cash & Short-term Investments | 239K | 2.40M | 10.1M | 1.35M |
| Cash Flow | ||||
| Operating Cash Flow | 315K | -3.68M | -13.4M | -6.34M |
| Capital Expenditure | 56.1K | 300K | 1.85M | 9.37M |
| Ratios | ||||
| ROE | - | 596.2% | -139.5% | -231.2% |
| ROA | -4.1% | 85.7% | -80.7% | -98.5% |
| Net Profit Margin | -1.7% | 53.1% | -610.5% | -263.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
RxElite Inc dividends
RxElite Inc has not paid dividends in the last 3 fiscal years.
Who owns RxElite Inc
Ownership data of RxElite Inc is not available yet.
RxElite Inc company profile
- Company name
- RxElite Inc
- Ticker
- RXEI.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 47
- Fiscal year end
- December
- Address
- 1404 North Main, Meridian, ID, United States, 83642
- Phone
- 208-288-5550
- Website
- piramalcriticalcare.com
About RxElite Inc
RxElite, Inc. engages in the development, manufacture, and marketing of generic prescription drug products in specialty generic markets. Its products include Sterile Liquid Dose products that consist of generic ophthalmic products in unit and multi-dose presentations, sterile unit dose inhalation respiratory products, and injectable drugs. The company, through its subsidiaries, also manufactures active pharmaceutical ingredients for pharmaceutical companies in the United States, Europe, and Asia. Its customers include hospitals and hospital group purchasing organizations, national and regional wholesalers, direct retail pharmacy stocking chains, homecare companies, and outpatient surgery centers and ambulatory care clinics. The company has partnership agreements with Stason Pharmaceuticals, Inc.; Alkem Laboratories Limited; and Zach Systems S.p.A. RxElite is headquartered in Meridian, Idaho. RxElite, Inc. was formerly a subsidiary of Piramal Enterprises Limited.
RxElite Inc management
1- Mr. Richard TenerVice President of Administration